Osimertinib, which is a targeted therapy, has been a major breakthrough in the treatment of NSCLC (NSCLC).The efficacy of osimertinib can be reduced by multiple factors, which in turn prompts the requirement for osimertinib dosage adjustment.The article aims to explore the reasons for this requirement and to discuss the demands associated with managing this therapeutic approach.Adverse effects such as skin eruption, diarrhoea, and liver disorder may be experienced by patients, which may hinder their ability to endure the standard dosage of osimertinib.It becomes essential to reduce the dose to reduce…
Treating lung cancer patients who have developed resistance to conventional therapy schedules requires the consideration of osimertinib decreased dosage reaction, which is a key element.This refers to the patient's response to reduced dosage of osimertinib, which is a precision medicine for NSCLC (non-small cell lung cancer) (NSCLC).For medical staff to optimize therapy plans and improve patient management, it is essential to understand the implications of dose reduction and its impact on patient results.Evaluating the effectiveness of reduced osimertinib dosage in patients with NSCLC is the first requirement.This requires conducting research…
